Antiplatelet drugs for polycythemia vera and essential thrombocythaemia

  • Protocol
  • Intervention

Authors

  • A Squizzato,

  • E Romualdi,

  • S Middeldorp


Alessandro Squizzato, Medicia Interna 1, Ospedale di Circolo, Viale Borri 57, 21100 Varese, 21100, ITALY. alexsquizzo@libero.it.

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

1. To quantify the potential benefit of an antiplatelet drug for long-term primary and secondary prophylaxis of arterial and venous thrombotic events in patients with polycythaemia vera or essential thrombocythaemia

2. To quantify the potential harm of an antiplatelet drug in term of bleedings (major and minor bleeding) and adverse effects (e.g. renal failure, TTP, neutropenia, low platelets, gastric complaints and diarrhoea) in patients with polycythaemia vera or essential thrombocythaemia